Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

Sermorelin

Sermorelin MolecularFormula | C149H246N44O42S / MolecularWeight | 3357.9 / IUPACName | (3S)-4-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)

By Recovery & Performance Peptides Editorial Team

Sermorelin

MolecularFormulaC149H246N44O42S
MolecularWeight3357.9
IUPACName(3S)-4-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-4-oxobutanoic acid
  • SERMORELIN
  • Sermorelina
  • 86168-78-7
  • Sermoreline
  • Sermorelinum
  • DTXSID70903978
  • 89243S03TE
  • TYR-ALA-ASP-ALA-ILE-PHE-THR-ASN-SER-TYR-ARG-LYS-VAL-LEU-GLY-GLN-LEU-SER-ALA-ARG-LYS-LEU-LEU-GLN-ASP-ILE-MET-SER-ARG-NH2
  • CHEBI:9118
  • Groliberin
  • hGHRH(1-29)NH2
  • RefChem:182524
  • GHRH(1-29)NH2
  • H01AC04
  • V04CD03
  • GRF(1-29)NH2
  • DTXCID301331916
  • Somatotropin-Releasing-Hormone(1-29)Amide
  • Growth Hormone-Releasing Factor(1-29)Amide
  • Sermoreline [French]
  • Sermorelinum [Latin]
  • Sermorelina [Spanish]
  • Sermorelin [INN:BAN]
  • SCHEMBL34139
  • UNII-89243S03TE
  • EX-A5534
  • BDBM50004966
  • AC-8930
  • AT52447
  • L-tyrosyl-L-alanyl-L-alpha-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-alpha-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-argininamide
  • Somatoliberin (human pancreatic islet), 29-L-argininamide-30-de-L-glutamine-31-de-L-glutamine-32-deglycine-33-de-L-glutamic acid-34-de-L-serine-35-de-L-asparagine-36-de-L-glutamine-37-de-L-glutamic acid-38-de-L-arginine-39-deglycine-40-de-L-alanine-41-de-L-arginine-42-de-L-alanine-43-de-L-argininyl-44-de-L-leucinamide
  • Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg(GRF(1-29)-NH2)
  • Tyr-Ala-Asp-Ala-Ile-Phe-Thr-D-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg(D-Asn8,(1-29)-NH2)
  • Tyr-Ala-D-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg(D-Asp3,(1-29)-NH2)
  • Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg(D-Ala2(1-29)-NH2)
CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosages

Sermorelin is administered through subcutaneous or intravenous injection, with dosages tailored to the patient’s age, condition, and treatment goals. For diagnostic purposes, such as evaluating growth hormone deficiency, clinicians typically administer a single dose of 1 mcg per kg of body weight intravenously. This stimulates the pituitary gland, allowing measurement of growth hormone release to assess pituitary function. In therapeutic settings, particularly for children with growth hormone deficiency, daily subcutaneous injections often range from 100 to 200 mcg, typically given at bedtime to align with the body’s natural growth hormone release cycle. Adult dosages, when used off-label to address growth hormone insufficiency, generally fall between 0.2 to 0.5 mg daily, adjusted based on clinical response and under medical supervision. Dosages require careful monitoring to ensure efficacy and safety, as user responses to sermorelin may vary.
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Human & Animal Studies

Human Studies Sermorelin and related GHRH(1-29) analogs have been studied in both children and adults. Clinical studies have evaluated sermorelin/GHRH therapy for: Growth hormone deficiency in children Idiopathic short stature or impaired growth velocity Diagnostic evaluation of GH reserve Age-related decline in GH secretion Effects on the somatotropic axis in older adults A review article describes sermorelin as a 29-amino-acid analog of human GHRH and the shortest synthetic peptide retaining full biologic activity of GHRH. In children with growth hormone deficiency, once-daily subcutaneous GHRH therapy was shown to accelerate growth during the first year of therapy. In older adults, nightly administration of a GHRH analog for four months activated the somatotropic axis, increasing GH and IGF-1 activity. Animal & Preclinical Studies Preclinical research on GHRH analogs has helped establish their biologic activity and receptor-mediated effects. Animal and laboratory studies have shown that GHRH analogs can: Stimulate pituitary GH release Increase downstream IGF-1 signaling Demonstrate receptor-specific activity at the GHRH receptor Support growth-related pathways Help characterize GH secretion physiology Animal and preclinical data support the biologic plausibility of sermorelin, but they do not establish safety or effectiveness for common off-label wellness uses in humans.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

Sermorelin vs Modified GRF 1-29

เปปไทด์ ทั้งสองชนิดนี้ไม่มีความแตกต่างกันมากนักในแง่ของการทำงาน อย่างไรก็ตาม มีความแตกต่างทางโครงสร้างบางประการที่สังเกตเห็นได้ กรดอะมิโนสี่ชนิดเฉพาะถูกเปลี่ยนแปลงใน Modified GRF …

Continue reading

Related articles

Sermorelin

Sermorelin is a synthetic peptide that mimics the function of growth hormone-releasing hormone (GHRH), stimulating the release of growth hormone (GH) from the pituitary gland. By increasing GH production, Sermorelin can…

Read article